Pacira Biosciences Inc reports results for the quarter ended in June - Earnings Summary

Pacira Biosciences

30/07/2024 22:01

* Pacira Biosciences Inc  PCRX.OQ  reported quarterly
adjusted
earnings of 89 cents​​ per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of 78 cents.  The mean expectation of nine analysts
for the quarter was for earnings of 70 cents per share. Wall
Street expected results to range from 53 cents to 83 cents per
share.
    * Revenue rose 5% to $178.02 million from a year ago;
analysts
expected $172.50 million. 
    * Pacira Biosciences Inc's reported EPS for the quarter was
39
cents​.
    * The company reported quarterly net income of $18.89
million.
    * Pacira Biosciences Inc shares had fallen by 28.9% this
quarter and lost 39.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 0.9%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Pacira
Biosciences Inc is $41.50 
This summary was machine generated from LSEG data July 30 at
09:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jan. 1 0001       0.70           0.89           Beat
 Mar. 31 2024      0.62           0.62           Met
 Dec. 31 2023      0.88           0.89           Beat
 Sep. 30 2023      0.78           0.72           Missed